SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 07:42:53 2024-05-28 EDT | ||
| 32.31 EUR | +0.81% |
|
| Current month | -0.84% | ||
| 1 month | -0.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 32.31 | +0.81% |
| 24-05-27 | 32.05 | -0.71% |
| 24-05-24 | 32.28 | +3.23% |
| 24-05-23 | 31.27 | +1.62% |
| 24-05-22 | 30.77 | -2.07% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 07:42 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0EM2 |
| ISIN | DE000VU0EM25 |
| Date issued | 2022-12-01 |
| Strike | 4,360 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.98 € |
|---|---|
| Lowest since issue | 14.41 € |
| Spread | 0.02 € |
| Spread % | 0.06% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,955
DKK
Average target price
2,466
DKK
Spread / Average Target
+26.13%
- Stock Market
- Certificates
- Certificat
